Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial.
- DOI
- 10.1038/s41408-021-00539-8
- Published
- 2021 Aug 20
- Container
- Blood cancer journal
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41408-021-00539-8,
title = {Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial.},
author = {Morschhauser F and Ghosh N and Lossos IS and Palomba ML and Mehta A and Casasnovas O and Stevens D and Katakam S and Knapp A and Nielsen T and McCord R and Salles G},
year = {2021},
journal = {Blood cancer journal},
doi = {10.1038/s41408-021-00539-8},
url = {https://doi.org/10.1038/s41408-021-00539-8}
}RIS
TY - JOUR TI - Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial. AU - Morschhauser F AU - Ghosh N AU - Lossos IS AU - Palomba ML AU - Mehta A AU - Casasnovas O AU - Stevens D AU - Katakam S AU - Knapp A AU - Nielsen T AU - McCord R AU - Salles G PY - 2021 JO - Blood cancer journal DO - 10.1038/s41408-021-00539-8 UR - https://doi.org/10.1038/s41408-021-00539-8 ER -
APA
F, M., N, G., IS, L., ML, P., A, M., O, C., D, S., S, K., A, K., T, N., R, M., & G, S. (2021). Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial.. Blood cancer journal. https://doi.org/10.1038/s41408-021-00539-8
Source records
- pubmed · retrieved 2026-09-26T14:11:12.075Z